This site is intended for healthcare professionals
News

Eli Lilly's neutralizing antibody bamlanivimab (LY-CoV555) receives FDA emergency use authorization for the treatment of recently diagnosed COVID-19.

Read time: 2 mins
Last updated:12th Nov 2020
Published:12th Nov 2020
Condition: Coronavirus/COVID-19 Infection
Type: drug
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest